Finance

Lists
Why is GLUE up ၉.၄၅%?
Dive Deeper
GLUE:NASDAQ
Monte Rosa Therapeutics Inc
၁၀.၆၆ US$
+၉.၄၅%
(+၀.၉၂) 1D
၁၀.၆၆ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: အောက် ၁၉, GMT-၄ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GLUE...
Open
၉.၈၄ US$
High
၁၀.၇၁ US$
Low
၉.၇၆ US$
Mkt. cap
၉၀.၉၄ ကုဋေ
Avg. vol.
၁.၄၀ သန်း
Volume
၁.၉၃ သန်း
52-wk high
၂၅.၇၇ US$
52-wk low
၈.၉၄ US$
EPS
-၁.၇၄ US$
Beta
၁.၃၇
Shares outstanding
၈.၅၃ ကုဋေ
No. of employees
၁၇၃
Open
၉.၈၄ US$
High
၁၀.၇၁ US$
Low
၉.၇၆ US$
Mkt. cap
၉၀.၉၄ ကုဋေ
Avg. vol.
၁.၄၀ သန်း
Volume
၁.၉၃ သန်း
52-wk high
၂၅.၇၇ US$
52-wk low
၈.၉၄ US$
EPS
-၁.၇၄ US$
Beta
၁.၃၇
Shares outstanding
၈.၅၃ ကုဋေ
No. of employees
၁၇၃
News stories
From web sources and news partners
MarketBeat
MarketBeat
·
ပြီးခဲ့သည့် ၁၁ နာရီ
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Jumps 8% - Here's What Happened
About Monte Rosa Therapeutics Inc
CEO-
Employees၁၇၃
Founded၂၀၁၉
Headquartersဘော့စတွန်မြို့, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Analyst ratings
Based on 8 analysts giving stock ratings to GLUE in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for GLUE in the last 3 months.
Highest
Current ၁၀.၆၆ US$
၃၇.၀၀ US$ (+၂၄၇.၀၉%)
Average
၂၆.၈၆ US$ (+၁၅၁.၉၇%)
Lowest
၁၉.၀၀ US$ (+၇၈.၂၄%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
UBS
Buy
Reiterated
၁၉.၀၀ US$
+၇၈.၂%
10/12/2026
Alice Nettleton
UBS
Buy
Initiated
၁၉.၀၀ US$
+၇၈.၂%
10/12/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
၂၅.၀၀ US$
+၁၃၄.၅%
10/05/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
-
-
10/02/2026
Robert Driscoll
Wedbush
Buy
Maintained
၂၇.၀၀ US$
+၁၅၃.၃%
10/02/2026
Unknown Analyst
Wedbush
Buy
Maintained
၂၇.၀၀ US$
+၁၅၃.၃%
10/02/2026
Michael Schmidt
Guggenheim
Buy
Maintained
၂၈.၀၀ US$
+၁၆၂.၇%
10/01/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
၃၇.၀၀ US$
+၂၄၇.၁%
10/02/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
၂၇.၀၀ US$
+၁၅၃.၃%
08/10/2026
Faisal Khurshid
Jefferies
Buy
Maintained
၂၅.၀၀ US$
+၁၃၄.၅%
07/31/2026
Derek Archila
Wells Fargo
Buy
Reiterated
၂၉.၀၀ US$
+၁၇၂%
06/24/2026
Marc Frahm
TD Cowen
Buy
Reiterated
-
-
05/07/2026
Last report
၂၀၂၆ ဩ ၆
Fiscal period
Q2 2026
-၀.၄၃ US$ / -၀.၃၇ US$
-၁၇.၅၈%miss
Revenue / Est. (USD)
၈.၉၇ သန်း / ၁.၂၉ ကုဋေ
-၃၀.၃၆%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၁.၂၈ ကုဋေ
၂.၇၈ သန်း
၄.၂၁ သန်း
၈.၉၇ သန်း
Cost of goods sold
၃.၄၆ ကုဋေ
၃.၉၉ ကုဋေ
၄.၁၈ ကုဋေ
၄.၆၀ ကုဋေ
Cost of revenue
၃.၄၆ ကုဋေ
၃.၉၉ ကုဋေ
၄.၁၈ ကုဋေ
၄.၆၀ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁.၁၁ ကုဋေ
၁.၂၆ ကုဋေ
၁.၂၄ ကုဋေ
၁.၂၁ ကုဋေ
Operating expense
၁.၁၁ ကုဋေ
၁.၂၆ ကုဋေ
၁.၂၄ ကုဋေ
၁.၂၁ ကုဋေ
Total operating expenses
၄.၅၇ ကုဋေ
၅.၂၅ ကုဋေ
၅.၄၂ ကုဋေ
၅.၈၁ ကုဋေ
Operating income
-၃.၃၀ ကုဋေ
-၄.၉၇ ကုဋေ
-၅.၀၀ ကုဋေ
-၄.၉၁ ကုဋေ
Other non operating income
-
-
-
-
EBT including unusual items
-၃.၀၃ ကုဋေ
-၄.၆၁ ကုဋေ
-၄.၄၅ ကုဋေ
-၄.၃၂ ကုဋေ
EBT excluding unusual items
-၃.၀၃ ကုဋေ
-၄.၆၁ ကုဋေ
-၄.၄၅ ကုဋေ
-၄.၃၂ ကုဋေ
Income tax expense
-၃.၁၈ သန်း
၅.၉၀ သောင်း
၅.၂၀ သောင်း
၂.၀၈ သိန်း
Effective tax rate
၁၀.၅၀%
-၀.၁၃%
-၀.၁၂%
-၀.၄၈%
Other operating expenses
-
-
-
-
Net income
-၂.၇၁ ကုဋေ
-၄.၆၁ ကုဋေ
-၄.၄၅ ကုဋေ
-၄.၃၄ ကုဋေ
Net profit margin
-၂၁၂.၁၀%
-၁,၆၅၈.၉၄%
-၁,၀၅၇.၀၈%
-၄၈၃.၉၁%
Earnings per share
-၀.၃၃
-၀.၅၅
-၀.၄၅
-၀.၄၃
Interest and investment income
၂.၇၅ သန်း
၃.၆၉ သန်း
၅.၅၉ သန်း
၅.၉၂ သန်း
Interest expense
-
-
-
-
Net interest expenses
၂.၇၅ သန်း
၃.၆၉ သန်း
၅.၅၉ သန်း
၅.၉၂ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၃.၀၉ ကုဋေ
-၄.၇၆ ကုဋေ
-၄.၈၀ ကုဋေ
-၄.၇၂ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ